Register by October 10th for eXpressions.

Learn how to bring Health Unleashed! to your school.

Enrollment for Dangerous Decibels begins in mid-September.

< Back to Search Results

Administration of the First Dose of Palivizumab (Synagis®) in an Inpatient vs Outpatient Setting

Adham Abushukur

View Poster View Presentation
School: Avon Lake High School
Internship Track: Applied Medicine
Year 2018
Mentor: Hany Aziz, MD, MS
Co-Mentor(s): Betsy Walters Burkey, PharmD, BCPS, BCPPS
Department(s): Neonatology Department
Abstract: Palivizumab (Synagis®) is a passive immunization used to prevent respiratory syncytial virus (RSV). It was approved for use by the FDA in 1998. Prior to the 2017-2018 season, all prior authorization for palivizumab was handled in the outpatient clinic. In the 2017-2018 season, the inpatient care team filed the prior authorization forms. This project’s hypothesis was that having the inpatient care team address the prior authorization for palivizumab should reduce the outpatient workload and may reduce the risk of administerin palivizumab outside of the recommended guidelines.